P
ProHub
English 简体中文 繁體中文
Medium Profitability Product Launch R&D Investment Decision

Fringe Science

#Healthcare
ProHub Comment

This is a sophisticated healthcare profitability case requiring candidates to integrate multiple quantitative and qualitative factors. The case tests market sizing, probability-weighted financial analysis, and strategic pricing decisions while incorporating healthcare-specific considerations like formulary status and clinical efficacy profiles. An excellent candidate must proactively identify the need for additional data, perform expected value calculations, and recognize that higher prices trade off against market access in healthcare markets.

Estimated Time 27 minutes
Difficulty Medium
Source Duke
10 / 100
Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

Clarifying Information

  1. Drug is only likely to be approved in the US at this time
  2. Drug will be sold directly to hospitals by Massive Dynamic; therefore, no need to consider distribution channel costs, etc.
  3. No need to calculate based on NPV, just do total over five years w/out discounting
  4. Provide Exhibit 1 when asked about market size and/or competition
  5. Provide Exhibit 2 when asked about development costs or clinical profile
  6. Provide Exhibit 3 after an initial indication selected and pricing prompt given
Mock Interview
Interviewer

Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

Massive Dynamic must choose between three fungal infection indications (Aspergillosis, Rare Molds, Candidiasis) for their promising drug Cortexiphan to maximize five-year post-launch profits. The case progressively reveals market data, clinical profiles, development costs, and pricing dynamics, requiring candidates to move beyond simple market sizing to strategic recommendation balancing clinical advantage, trial success probability, and pricing strategy.

Key Insights:

  1. Market size alone is insufficient; must weight by probability of trial success, clinical profile competitiveness, and competitive intensity
  2. Expected value analysis requires integrating both upside (if successful) and downside risk (trial failure costs) to make optimal capital allocation decisions
  3. Healthcare pricing involves non-linear tradeoffs: premium pricing generates higher per-unit revenue but worsens formulary status and market access, requiring careful optimization
  4. Superior clinical profile in a moderately-sized market may outperform inferior profile in larger market due to competitive dynamics and market share constraints
  5. Excellent candidates customize frameworks to industry-specific factors rather than applying generic profitability analysis